Company Active PRIVATE-LIMITED-GUARANT-NSC

Company profile

The Cambridge Crystallographic Data Centre

The Cambridge Crystallographic Data Centre is a UK company with status active founded in 1987 based in East of England.

CRN
02155347
Founded
1987
Age
38

Overview

Legal name
THE CAMBRIDGE CRYSTALLOGRAPHIC DATA CENTRE
Region
East of England
Registered address
12 UNION ROAD
CAMBRIDGE
CAMBRIDGESHIRE
CB2 1EZ
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

9 events
05 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

19 Jun
2026

Accounts With Accounts Type Group

Accounts PDF pending

AA | Transaction MzUyNjE4NzA4MmFkaXF6a2N4 | Paper/PDF filed

Published 19 Jun 2026 22:41

21 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

22 Nov
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0NDU3OTE3NGFkaXF6a2N4

Published 22 Nov 2024 11:07

22 Nov
2024

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzQ0NDU3ODIzNGFkaXF6a2N4

Published 22 Nov 2024 11:00

09 Oct
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzODg5OTIxMWFkaXF6a2N4

Published 09 Oct 2024 09:09

18 Aug
1987

Incorporated

Inception

Company registered at Companies House

Public funding

7 awards
First funded
2020
Funded years
2020, 2024, 2025
Age at first award
32 years

Projects

2025 Collaborative R&D Lead participant

DigiCCAMMS: Digital Crystallisation Control for Advanced Medicines Manufacturing Sustainability

1 Feb 2025 to 31 Jan 2027

Awarded
£472,433
Total cost £787,388

Crystallisation is the process of forming a solid crystal from a solution of molecules. It is an important process in the development and manufacturing of small molecule new medicines. The crystalline particles that go into "solid dosage forms" of medicines like tablets and inhalation drugs (where clinical performance is directly correlated to particle be...

2025 Feasibility Studies

DPN-MED: Digital Plug-and-Produce Network for Sustainable Medicines Development and Manufacturing

1 Jan 2025 to 30 Jun 2025

Awarded
£10,021
Total cost £10,021

The pharmaceutical industry is a major contributor to global greenhouse gas (GHG) emissions, with the UK healthcare sector accounting for 5% of the nation's total emissions, 20% of which are linked to medicines. Pharmaceutical emissions are 55% higher than those of the automotive industry, generating up to 100 kg of waste per kg of product. This carbon fo...

2024 Collaborative R&D

SHARPEN: SHARing data to accelerate Pharmaceutical manufacturing Efficiency across trusted Networks; A Framework for Risk Assessing the Value of Federated Learning to Improve the Fidelity of Models in Pharmaceutical Manufacturing

1 Aug 2024 to 31 Jan 2026

Awarded
£244,844
Total cost £408,073

The Pharmaceutical industry is really good at employing molecular-level chemistry models to help predict likely new cures for diseases. On the flip side it is bad (vs. other industries) at applying modelling to manufacturing to predict how and when to make products most effectively. This is for a number of reasons, one of which is the lack of good quality...

2024 Collaborative R&D

A Regulatory Science Network for the Digital Transformation of Medicines Development and Manufacturing

1 Mar 2024 to 31 Aug 2024

Awarded
£13,630
Total cost £13,630

Ensuring reliable access to affordable, safe, effective, sustainable, and high-quality 21st-century medicines requires 21st-century technologies and, crucially, harmonised, effective and innovative regulatory approaches. This UK regulatory science network aims to deliver the 21st-century regulatory science and innovation needed to unlock the benefits of t...

2020 Knowledge Transfer Partnership

University of Leeds (The) and Cambridge Crystallographic Data Centre (The)

1 Oct 2020 to 31 Jul 2023

Awarded
Unknown

To develop and bring to market a state-of-the-art digital design platform to significantly automate, streamline and accelerate the design, development and manufacturing processes for pharmaceutical products.

2020 Collaborative R&D

Next-generation Digital Design technology for Formulated Products involving complex materials

1 Jul 2020 to 30 Jun 2022

Awarded
£121,122
Total cost £201,870

New therapeutic products in the pharma industries are invariably large, complex chemical molecules -- e.g., synthetic active ingredients, amino acids, peptides etc. In the consumer goods and food industries, complex emulsions form the backbone of products such as detergents, beauty products, milk and other liquid-based foods. An essential pre-requisite fo...

2020 Collaborative R&D

Digital Design Accelerator Platform to Connect Active Material Design to Product Performance

1 Mar 2020 to 31 Aug 2022

Awarded
£173,226
Total cost £288,710

.

Product types

Collaborative R&D Feasibility Studies Knowledge Transfer Partnership